Phaseline

Targets › MPL

MPL (Thrombopoietin receptor): drug programs, companies and trials

7 programs from 7 companies in 39 trials: 23 Phase 2, 7 Phase 4, 6 Phase 3, 3 Phase 1; Hematology, Oncology, Other; next expected readout Dec 2026.

Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K. In turn, These signaling cascades lead to the proliferation, survival, and differentiation of…. (UniProt, P40238)

Open in Phaseline: the race on MPL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Al-Mustansiriyah UniversityAvatrombopag
Thrombopoietin receptor agonist
MPLPhase 4ITP - Immune ThrombocytopeniaJul 2027
AmgenRomiplostim
Thrombopoietin receptor agonist
MPLPhase 3Chemotherapy-induced Thrombocytopenia; Primary Immune Thrombocytopenia; CTIT: Cancer Therapy Induced Thrombocytopenia; Solid Tumors …Feb 2027
Jiangsu HengRui MedicineHetrombopag Olamine
Thrombopoietin receptor agonist
MPLPhase 3Chemotherapy-Induced Thrombocytopenia; Patients With Chemotherapy-Induced Thrombocytopenia; ITP - Immune Thrombocytopenia; Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors …Dec 2028
NovartisEltrombopag
Thrombopoietin receptor agonist
MPLPhase 2Myelodysplastic SyndromesDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaAvatrombopag
Thrombopoietin receptor agonist
MPLPhase 2Immune Thrombocytopenia–
Anhui Provincial HospitalLusutrombopag
Thrombopoietin receptor agonist
MPLPhase 2Thrombocytopenia–
RenataEltrombopag
Thrombopoietin receptor agonist
MPLPhase 1Primary Immune Thrombocytopenia; Healthy; Hematological Neoplasms; ITP - Immune Thrombocytopenia …–

Conditions

Primary Immune Thrombocytopenia (3) ITP - Immune Thrombocytopenia (3) Primary Immune Thrombocytopenia (ITP) (3) Chemotherapy-induced Thrombocytopenia (3) Immune Thrombocytopenia (3) Severe Aplastic Anemia (2) Persistent Isolated Chemotherapy-Induced Thrombocytopenia (2) Healthy (1) Hematological Neoplasms (1) Fanconi Anemia (1) Myelodysplastic Syndromes (1) Chemotherapy-Induced Thrombocytopenia (1)

Modalities

small molecule (7)

Companies

Renata (1) Al-Mustansiriyah University (1) Novartis (1) Jiangsu HengRui Medicine (1) Amgen (1) Institute of Hematology & Blood Diseases Hospital, China (1) Anhui Provincial Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.